Survodutide to advance into three global Phase III studies in obesity
Boehringer Ingelheim announced it will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III studies for people living with overweight or obesity
This decision was based on recently presented data from a Phase II dose finding study in people living with overweight or obesity. The study demonstrated up to 19 percent weight loss after 46 weeks of treatment with survodutide.
Insights from previous studies will now be applied to the design of three global Phase III studies, which will investigate the efficacy and safety of survodutide. Details of the studies will be disclosed prior to their initiation and enrollment of patients is planned before the end of 2023.
Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which are critical to controlling metabolic functions. It is also evaluated in a Phase II study in adults with NASH and liver fibrosis (stages F1/F2/F3) with and without type 2 diabetes for which it received US FDA Fast Track Designation. Co-invented by Boehringer Ingelheim and Zealand Pharma, survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardio-renal-metabolic disease areas.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.